Inhibrx Biosciences, Inc.
INBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $153 | $187 | $217 | $153 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $1 | $1 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $7 | $6 | $7 | $7 |
| Total Curr. Assets | $161 | $194 | $223 | $160 |
| Property Plant & Equip (Net) | $10 | $11 | $12 | $14 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $6 | $7 | $7 | $7 |
| Total NC Assets | $16 | $18 | $19 | $20 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $177 | $212 | $243 | $181 |
| Liabilities | – | – | – | – |
| Payables | $7 | $8 | $9 | $9 |
| Short-Term Debt | $2 | $2 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $27 | $28 | $33 | $30 |
| Total Curr. Liab. | $36 | $39 | $44 | $41 |
| LT Debt | $5 | $105 | $105 | $6 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $100 | $0 | $0 | $0 |
| Total NC Liab. | $105 | $105 | $105 | $6 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $8 | $8 | $6 |
| Total Liabilities | $141 | $144 | $148 | $47 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$213 | -$178 | -$149 | -$106 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $250 | $247 | $244 | $240 |
| Total Equity | $37 | $69 | $94 | $134 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $177 | $212 | $243 | $181 |
| Net Debt | -$146 | -$80 | -$110 | -$145 |